TABLE 3.
Patient characteristics of patients having episodes with PCR/ESI-MS-discordant and -concordant results compared with BCa
| Patient characteristic | PCR/ESI-MS concordant (n = 13)b | PCR/ESI-MS nonconcordant (n = 14)c | Significance (P value) |
|---|---|---|---|
| Age (mean [range]) (yr) | 52 (19–65) | 50 (20–67) | 0.72 |
| Males/females | 8/5 | 7/7 | 0.36 |
| Patients with absolute WBC count (109/liter) at time of sampling of: | 0.24 | ||
| <0.5 | 11 | 13 | |
| 0.5–2 | 2 | 1 | |
| Patients with absolute neutrophil count (109/liter) at time of sampling of: | 0.57 | ||
| <0.1 | 11 | 13 | |
| 0.1–0.5 | 1 | 1 | |
| 0.6–1.5 | 1 | 0 | |
| >1.5 | 0 | 0 | |
| Blood culture bottles collected at time of PCR/ESI-MS sample (median [range]) | 8 (4–8) | 8 (2–8) | 0.61 |
| Percent blood culture bottles positive collected at the time of PCR/ESI-MS sample (mean [range]) | 78 (38–100) | 48 (13–100) | 0.02 |
| Patients with only positive blood culture(s) collected from a different site than the site where the PCR/ESI-MS sample was collected | 1 | 3 | |
| Patients with stem cell transplantation | 6 | 10 | 0.35 |
| Allogeneic | 5 | 7 | |
| Autologous | 1 | 3 | |
| Underling disease | |||
| Hematologic malignancy (%) | 13 (100) | 14 (100) | |
| Acute myeloid leukemia | 6 | 8 | |
| Chronic myeloid leukemia | 0 | 1 | |
| Myelodysplastic syndrome | 0 | 1 | |
| Myeloproliferative neoplasm | 0 | 0 | |
| Acute lymphoid leukemia | 4 | 0 | |
| B-cell non-Hodgkin lymphoma | 1 | 4 | |
| T-cell neoplasm | 2 | 0 | |
| Patients with chemotherapy at time of sampling (including 24 h before sample) | 5 | 4 | 0.55 |
| Patients (%) with antibiotic therapy at time of sampling using: | 13 (100) | 14 (100) | |
| Levofloxacin | 9 | 13 | |
| Meropenem | 2 | 1 | |
| Vancomycin | 1 | 0 | |
| Ceftazidime | 1 | 0 | |
| Fluconazole | 10 | 12 | |
| Acyclovir | 6 | 8 |
a
Values are the number, unless otherwise predicted.
b
PCR/ESI-MS and BC detected same MO.
c
BC positive and PCR/ESI-MS negative or MO not detected.